- Home
- VOR vs GNFT Comparison
VOR vs GNFT Comparison
Compare VOR & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- GNFT
- Stock Information
- Founded
- VOR 2015
- GNFT 1999
- Country
- VOR United States
- GNFT France
- Employees
- VOR N/A
- GNFT N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOR Health Care
- GNFT Health Care
- Exchange
- VOR Nasdaq
- GNFT Nasdaq
- Market Cap
- VOR 207.1M
- GNFT 216.7M
- IPO Year
- VOR 2021
- GNFT 2019
- Fundamental
- Price
- VOR $29.40
- GNFT $4.16
- Analyst Decision
- VOR Buy
- GNFT Strong Buy
- Analyst Count
- VOR 6
- GNFT 2
- Target Price
- VOR $85.33
- GNFT $10.00
- AVG Volume (30 Days)
- VOR 526.1K
- GNFT 10.9K
- Earning Date
- VOR 11-06-2025
- GNFT 09-22-2025
- Dividend Yield
- VOR N/A
- GNFT N/A
- EPS Growth
- VOR N/A
- GNFT N/A
- EPS
- VOR N/A
- GNFT N/A
- Revenue
- VOR N/A
- GNFT $52,994,715.00
- Revenue This Year
- VOR N/A
- GNFT $3.14
- Revenue Next Year
- VOR N/A
- GNFT N/A
- P/E Ratio
- VOR N/A
- GNFT N/A
- Revenue Growth
- VOR N/A
- GNFT N/A
- 52 Week Low
- VOR $2.62
- GNFT $2.55
- 52 Week High
- VOR $65.80
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- VOR 52.41
- GNFT 53.45
- Support Level
- VOR $28.65
- GNFT $4.02
- Resistance Level
- VOR $31.31
- GNFT $4.41
- Average True Range (ATR)
- VOR 3.26
- GNFT 0.18
- MACD
- VOR -1.89
- GNFT 0.02
- Stochastic Oscillator
- VOR 2.79
- GNFT 56.06
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.